NDUFC2

NDUFC2 is a structural subunit of mitochondrial respiratory chain complex I that is specifically required for assembly of the membrane arm (ND2 module) of the holoenzyme; bi-allelic loss-of-function variants cause stalled complex I biogenesis, severely reduced complex I activity, and Leigh syndrome in humans (PMID:32969598). Loss of NDUFC2 leads to decreased mitochondrial membrane potential, reduced ATP production, increased reactive oxygen species, and ultrastructural disintegration of mitochondrial cristae, phenotypes demonstrated in both rodent knockout models and human cells carrying low-expression variants (PMID:26888427, PMID:28973657). Downstream of this mitochondrial dysfunction, NDUFC2 deficiency drives cardiomyocyte hypertrophy through the SIRT3–AMPK–AKT–MnSOD pathway and promotes NLRP3 inflammasome–dependent endothelial-to-mesenchymal transition under ischemic conditions (PMID:37558995, PMID:37506315).

1. 2016 High

   Establishing that NDUFC2 is functionally required for complex I activity in vivo resolved whether this small subunit is dispensable or essential: Ndufc2 knockout rats showed impaired complex I assembly, reduced membrane potential and ATP, elevated ROS, inflammation, and stroke susceptibility.

   Evidence Ndufc2 heterozygous knockout rat model with in vitro and in vivo functional assays including membrane potential, ATP, and ROS measurements

   PMID:26888427

   Open questions at the time

   • Precise step of complex I assembly at which NDUFC2 acts was not resolved
   • Mechanism linking NDUFC2 loss to inflammation was not defined
   • No human genetic disease association yet established
2. 2017 High

   Extending findings to human cells and ultrastructural analysis demonstrated that NDUFC2 deficiency causes cristae destruction and that mitochondrial damage is exacerbated by environmental stressors, confirming cross-species conservation of the phenotype.

   Evidence Rat knockout fibroblasts and human PBMCs from subjects homozygous for a low-expression NDUFC2 variant; cytofluorimetry, TEM, ROS assays

   PMID:28973657

   Open questions at the time

   • Human variant was a common low-expression allele, not a clear loss-of-function mutation
   • Structural basis of cristae disorganization was not determined
3. 2019 Medium

   Demonstrating that NDUFC2 silencing impairs vascular cell viability and angiogenesis connected complex I dysfunction to atherogenic mechanisms, expanding the disease relevance beyond stroke.

   Evidence siRNA knockdown in human endothelial and vascular smooth muscle cells; viability and angiogenesis assays, plaque-rupture marker expression

   PMID:30808603

   Open questions at the time

   • Single-lab knockdown without genetic rescue or animal model validation
   • No direct link to complex I assembly intermediates in vascular cells
   • Mechanism by which mitochondrial dysfunction triggers plaque-rupture markers not resolved
4. 2020 High

   Complexome profiling of patient fibroblasts with bi-allelic NDUFC2 loss-of-function variants pinpointed the assembly defect to the ND2 membrane-arm module and established NDUFC2 mutations as a cause of Leigh syndrome, definitively placing the subunit in the complex I biogenesis pathway.

   Evidence Patient fibroblasts with bi-allelic variants; complexome profiling, blue-native PAGE, lentiviral complementation rescue

   PMID:32969598

   Open questions at the time

   • Structural contacts between NDUFC2 and ND2 module components not mapped
   • Whether residual subassemblies retain partial electron-transfer activity was not tested
5. 2023 Medium

   Identification of downstream signaling cascades — SIRT3–AMPK–AKT–MnSOD in cardiomyocyte hypertrophy and NLRP3 inflammasome–driven endothelial-to-mesenchymal transition under ischemia — provided mechanistic links between NDUFC2-dependent mitochondrial dysfunction and specific cardiovascular pathologies.

   Evidence siRNA knockdown in H9c2 cells/primary cardiomyocytes and NDUFC2 overexpression in HBMECs under OGD/R; NLRP3 KO mice with tMCAO

   PMID:37506315 PMID:37558995

   Open questions at the time

   • Signaling pathway studies are single-lab and rely on knockdown/overexpression without genetic models
   • Whether SIRT3 and NLRP3 pathways interact or represent independent consequences of NDUFC2 loss is unknown
   • In vivo cardiac phenotypes of NDUFC2 deficiency have not been fully characterized

• The structural basis of NDUFC2's role in ND2 module assembly — including its direct protein contacts within the membrane arm, how its absence stalls the assembly intermediate, and whether pharmacological intervention can bypass or compensate for NDUFC2 loss — remains unresolved.
• No high-resolution structural data defining NDUFC2 contacts within the ND2 module
• No reconstitution of the assembly defect with purified components
• Genotype–phenotype spectrum across different NDUFC2 variants is not established